Browse the evidence

Current guidelines provide limited recommendations for the medical management of patients with obesity-related HFpEF.

Healthcare providers may need to seek additional resources for managing obesity-related HFpEF.

The role of GLP-1 receptor agonists in obesity-related HFpEF remains unclear.

Further research is needed to clarify the role of GLP-1 receptor agonists in managing obesity-related HFpEF.

Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.

GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.

Nineteen approved and pending Medicaid Section 1115 waivers address nutrition, with eleven submitted or approved since 2021.

Practitioners should be aware of the increasing number of waivers addressing nutrition in Medicaid.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

There was no difference in mean total body weight change between IBD and non-IBD cohorts after semaglutide initiation.

Weight loss outcomes with semaglutide appear consistent regardless of IBD status.

Common complications associated with GLP-1 RA treatment include nausea, constipation, abdominal pain, and vomiting.

Healthcare providers should monitor patients for these common side effects when prescribing GLP-1 RA.

Disparities in the use of SGLT-2 inhibitors and GLP-1 receptor agonists exist based on race, sex, and socioeconomic status.

Efforts should be made to address these disparities in prescribing practices.

Traditional recommendations for obesity treatment are largely ineffective.

Practitioners should be aware that traditional methods may not yield results.

23% of participants reported any adverse event while using GLP-1RAs, with 7% discontinuing treatment.

While GLP-1RAs are generally well-tolerated, practitioners should monitor for adverse events.

Treatment of wild-type mice with linolenic acid reduced food intake and body mass.

Using linolenic acid may help reduce food intake and body mass in certain contexts.

Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).

Clinicians should monitor for NAION in patients treated with semaglutide.

Current evidence remains insufficient to establish definitive conclusions regarding the association of semaglutide with NAION.

Further research is needed to clarify the risk of NAION with semaglutide.

The screening criteria for sarcopenic obesity include BMI, waist circumference, calf circumference, the SARC-F, and the Finger Ring test.

These criteria can guide practitioners in screening for sarcopenic obesity.

Benefits of the intervention were not evident for those entering the trial with a history of cardiovascular disease.

Practitioners should consider individual health histories when recommending lifestyle interventions.

The extra amount of protein led to minor changes in body composition but not physical performance or muscle quality.

Practitioners should manage expectations regarding the impact of increased protein on physical performance and muscle quality.

FIM programs often prioritize health equity.

Health care providers should ensure that FIM interventions are designed to promote health equity.

The use of mixed methods does not reach acceptable accuracy for 1RM prediction on an individual basis.

Practitioners should be cautious when using mixed methods for individual 1RM predictions.

There are concerns regarding the long-term safety and efficacy of GLP-1 receptor agonists.

Practitioners should monitor patients closely for safety and efficacy when prescribing GLP-1 receptor agonists.

Obesity is a disorder of energy metabolism characterized by low usable energy (ATP) in the setting of elevated total energy.

Practitioners should consider the role of energy metabolism in obesity management.

Treatment response heterogeneity is an important area of research in personalized and precision medicine.

Researchers should focus on understanding individual responses to treatments in nutrition and obesity.

The safety profile of tirzepatide is consistent across all phase 3 trials.

Practitioners can expect a consistent safety profile when prescribing tirzepatide.

Effect sizes of GLP-1 receptor agonists in schizophrenia are mostly smaller than in the general population.

While GLP-1 receptor agonists can aid in weight loss, practitioners should manage expectations regarding the magnitude of effect in this population.

Future trials of GLP-1 receptor agonists could focus on dual or triple agonist agents.

Exploring dual or triple agonist therapies may enhance treatment options for weight management in schizophrenia.